Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

FDA Grants Priority Review to Maintenance Rucaparib for Ovarian Cancer

Jason M. Broderick @jasoncology
Published: Wednesday, Dec 06, 2017

Patrick J. Mahaffy

Patrick J. Mahaffy
The FDA has granted a priority review to a supplemental new drug application (sNDA) for rucaparib (Rubraca) for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the manufacturer of the PARP inhibitor.

 <.0001). The ORRs were 27% (10 CRs) and 12% (0 CRs) for rucaparib and placebo, respectively.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication